Skip to main content
SpringerLink
Log in

Effect of Inhaled Corticosteroids on Salival Composition: A Cross-Sectional Study in Patients with Bronchial Asthma

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background

To date, no evidence exists in the literature as to the effects of inhaled corticosteroids (ICs) on salivary composition in patients with bronchial asthma.

Objective

The aim of this study was to assess the effect of ICs on salival composition.

Methods

Adult patients attending an outpatient respiratory clinic who were classified into two groups (controls and patients with bronchial asthma receiving ICs), were recruited in this cross-sectional study. For each participant, data of clinical records, baseline history of asthma, and regular IC dose were recorded. A sample of stimulated saliva was collected and processed for investigation of mucin 5B (MUC5B), lipoxygenase (LPO), total antioxidant capacity, and 8-hydroxydeoxyguanosine (8-OHdG) levels.

Results

Overall, 103 patients (49 controls and 54 patients receiving regular treatment with ICs) were recruited. No differences in comorbidities or smoking habits were observed. Patients treated with high-doses of ICs showed lower levels of salival MUC5B compared with those treated with medium IC doses or those not treated with ICs (1.60 vs. 2.20 vs. 2.53 ng/mL; p = 0.042).

Conclusion

In patients with asthma, treatment with high-doses of ICs is associated with reduced levels of salivary MUC5B. This effect can explain some of the effects of ICs on oral health.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2014. Available at: www.ginasthma.org. Accessed 12 May 2015.

  2. Spanish guidelines for asthma management (GEMA). 2009. Available at: www.gemasma.com. Accessed 12 May 2015.

  3. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ. 2014;349:g5517.

    Article  PubMed  Google Scholar 

  4. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;(5):CD002314.

  5. O’Byrne PM, Naya IP, Kallen A, Postma DS, Barnes PJ. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008;134:1192.

    Article  PubMed  Google Scholar 

  6. Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56:944–8.

    Article  CAS  PubMed  Google Scholar 

  7. Godara N, Godara R, Khullar M. Impact of inhalation therapy on oral health. Lung India. 2011;28:272–5.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Pramanik R, Osailan SM, Challacombe SJ, Urquhart D, Proctor GB. Protein and mucin retention on oral mucosal surfaces in dry mouth patients. Eur J Oral Sci. 2010;118:245–53.

    Article  CAS  PubMed  Google Scholar 

  9. Zalewska A, Zwierz K, Zółkowski K, Gindzieński A. Structure and biosynthesis of human salivary mucins. Acta Biochim Pol. 2000;47:1067–79.

    CAS  PubMed  Google Scholar 

  10. Frenkel ES, Ribbeck K. Salivary mucins protect surfaces from colonization by cariogenic bacteria. Appl Environ Microbiol. 2015;81:332–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387:147–63.

    Article  CAS  PubMed  Google Scholar 

  12. García-Río F, Calle M, Burgos F, et al. Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2013;49:388–401.

    Article  PubMed  Google Scholar 

  13. Dweik RA, Boggs PB, Erzurum SC, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol. 1998;108:101–6.

    CAS  PubMed  Google Scholar 

  15. Tabak LA, Levine MJ, Mandel ID, Ellison SA. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol. 1982;11:1–17.

    Article  CAS  PubMed  Google Scholar 

  16. Dijkema T, Terhaard CH, Roesink JM, et al. MUC5B levels in submandibular gland saliva of patients treated with radiotherapy for head-and-neck cancer: a pilot study. Radiat Oncol. 2012;7:91.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Caffery B, Heynen ML, Joyce E, Jones L, Ritter R, Senchyna M. MUC1 expression in Sjogren’s syndrome, KCS, and control subjects. Mol Vis. 2010;16:1720–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Alcázar-Navarrete B, Gómez-Moreno G, Aguilar-Salvatierra A, Guardia J, José Romero Palacios P. Xerostomia relates to the degree of asthma control. J Oral Pathol Med. 2015;44:273–7.

    Article  PubMed  Google Scholar 

  19. Gómez-Moreno G, Aguilar-Salvatierra A, Guardia J, et al. The efficacy of a topical sialogogue spray containing 1 % malic acid in patients with antidepressant-induced dry mouth: a double-blind, randomized clinical trial. Depress Anxiety. 2013;30:137–42.

    Article  CAS  PubMed  Google Scholar 

  20. Gómez-Moreno G, Guardia J, Aguilar-Salvatierra A, et al. Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs. Med Oral Patol Oral Cir Bucal. 2013;18:e49–55.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Mrs. Huda Khaldy from the Immunoanalysis and Radiobiochemistry Unit, University of Granada, who made the determination of salivary compounds possible.

Author information

Authors and Affiliations

  1. Pneumology Department, Hospital de Alta Resolución de Loja, Granada, Spain

    Bernardino Alcázar Navarrete

  2. Department of Medicine, School of Medicine, University of Granada, Avda de Madrid 11, 18011, Granada, Spain

    Bernardino Alcázar Navarrete & Pedro José Romero Palacios

  3. Department of Pharmacological Research in Dentistry, Special Care in Dentistry, School of Dentistry, University of Granada, Granada, Spain

    Antonio Aguilar-Salvatierra, Javier Guardia & Gerardo Gómez-Moreno

Authors
  1. Bernardino Alcázar Navarrete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro José Romero Palacios
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Aguilar-Salvatierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javier Guardia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerardo Gómez-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pedro José Romero Palacios.

Ethics declarations

Funding

This study was funded by Fundación Respira 255|2012 and FIS Project PI10/00932 of the Spanish Ministry of Science and Innovation, Health Institute Carlos III, in the hallmark of Research Group CTS-654 ‘Investigación Farmacológica en Odontología’ from Junta de Andalucía (Spain).

Conflict of interest

Bernardino Alcázar Navarrete reports receiving personal fees from Novartis AG, Boehringer-Ingelheim, GlaxoSmithKline, Almirall, and Astra-Zeneca, as well as grants and personal fees from Menarini, outside the submitted work. Pedro José Romero Palacios, Antonio Aguilar-Salvatierra, Javier Guardia, and Gerardo Gómez-Moreno have no conflicts of interest to disclose.

Ethical approval

This study was performed in accordance with the Declaration of Helsinki 1964 and its amendments. The study protocol, patient information and informed consent form were reviewed and approved by the responsible Ethics Committee of the Faculty of Medicine and Dentistry, University of Granada, Granada, Spain.

Informed consent

Informed consent was obtained from all individual participants in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Navarrete, B.A., Palacios, P.J.R., Aguilar-Salvatierra, A. et al. Effect of Inhaled Corticosteroids on Salival Composition: A Cross-Sectional Study in Patients with Bronchial Asthma. Clin Drug Investig 35, 569–574 (2015). https://doi.org/10.1007/s40261-015-0313-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-015-0313-7

Keywords

Search

Navigation